Hepatocellular carcinoma in elderly patients: a concise review on systemic therapy with sorafenib

Lombardi Giuseppe¹, Vitale Alessandro², Sara Lonardi¹, Bellu Luisa¹, Pambuku Ardi¹, Marsico Valentina¹, Crivellari Gino¹, Aliberti Camillo³, Cillo Umberto², Zagonel Vittorina¹

¹Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology-IRCCS, 35128 Padua, Italy
²Department of Surgery, Oncology and Gastroenterology, University of Padua, 35122 Padua, Italy
³Interventional Oncology Unit, Veneto Institute of Oncology-IRCCS, 35128 Padua, Italy

ABSTRACT
The treatment of hepatocellular carcinoma (HCC) in elderly patients is unclear. In particular, the efficacy and safety of sorafenib as a systemic treatment in these patients is still under debate. We performed a concise review of sorafenib therapy in this population. However, it is important to make any decisions on treatment for elderly patients with HCC through a multidisciplinary team that includes experts in the liver disease. Patients with good clinical conditions should be treated with sorafenib.

Key words: Hepatocellular carcinoma; sorafenib; treatment; chemotherapy; elderly patients

INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common solid organ malignancy worldwide and the second cause of cancer-related mortality, with the highest incidence rates in areas where hepatitis B virus infection is endemic such as South-East Asia and sub-Saharan Africa. Similar to other common cancers, the incidence of HCC increases in relation to age. In Western countries, it tends to peak at the age of 75 years and in the United States it rarely occurs before the age of 40 years. In Chinese and in black African populations, it generally occurs in younger patients.

Well-known risk factors typically characterize the development of HCC. The most frequent conditions include chronic viral hepatitis (types B and C), alcohol intake, and aflatoxin exposure. Cirrhosis is another important risk factor, which may be triggered by chronic viral hepatitis, alcohol or inherited metabolic diseases. Therefore, in up to 90% of cases, HCC becomes progressively worse on account of underlying liver diseases so that in most patients, prognosis and management are influenced by the presence of two separate entities: Chronic hepatitis with or without cirrhosis and HCC. Consequently, the choice of the appropriate HCC therapy should consider the limitations presented by underlying liver diseases.

In the most recent HCC guidelines (EASL/EORTC, AASLD, AISF, AIOM), disease staging includes tumor characteristics, underlying liver cirrhosis, and performance status. Treatment allocation is then based on these parameters. Patient age is not taken into account though there is an increasing focus on elderly patients. Due to the aging of the population, this group represents the fastest growing segment of populations with cancer.

The aim of this investigation was to review all the gathered experience of using sorafenib, a targeted multikinase inhibitor, in the treatment of HCC, with a focus on the evaluation of safety and the efficacy of this agent in the elderly as compared to younger patients.
DEFINITION OF “ELDERLY PATIENT”

Due to the fact that aging involves a progressive shortening of life expectancy and reduction in the functionality of organ systems, the definition of an “elderly patient” is somewhat hazy and still a matter of debate. What is the upper limit of age in which a patient is considered as old? Should the cut-off of 70 years used in clinical studies and in current clinical practice to be considered an acceptable and reasonable boundary? Is age the only parameter to take into account for defining an elderly patient or should the so-called stage of aging be evaluated more extensively? It has been demonstrated that the standardized geriatric evaluation systems, assessing additional parameters such as comorbidities, cognitive, and health status, may better correlate with therapy toxicity and patient outcomes, and could subsequently supply additional information to the standard performance status scale, such as KPS or ECOG PS, normally used in oncology. However, there has yet to be a general consensus on what the best geriatric evaluation system to use is.

Due to their fragile conditions, elderly patients are generally perceived to be more susceptible to the toxic effects of cancer therapy and, as a result, gain less clinical benefits from treatments due to frequent dose interruptions or permanent discontinuations of the drug. This perception could be related to the fact that this population is underrepresented in clinical trials, which are often conducted excluding patients exceeding a certain age limit or those bearing comorbidities.

However, a growing body of evidence suggests that older patients with adequate organ function and a reasonable life expectancy should receive the same treatment as younger patients. A retrospective analysis is evaluating 13 different molecularly targeted cancer therapies found similar frequencies of drug-related adverse events among the elderly as in younger patients. To limit this gap and identify the most appropriate treatment of elderly patients, it is advisable to assess how available treatment options behave in the framework of both well-conducted clinical trials and in everyday clinical practice.

TREATMENT WITH SORAFENIB

Therapeutic options for HCC range from surgeries (resection or liver transplantation) to loco-regional therapies (percutaneous ethanol injection, radiofrequency ablation or trans-arterial chemo-embolization) and systemic treatment, depending either on the stage of tumor disease or on the underlying liver disease. Currently, treatment with sorafenib has been recognized as the only standard systemic therapy for HCC. It is indicated for patients with well-preserved liver function (Child-Pugh A class) and with advanced tumors or for those with tumor progressing upon loco-regional therapies.

The efficacy of sorafenib in HCC was established in SHARP, and Asian-Pacific, two randomized, phase III multicenter, double-blind, placebo-controlled trials that led to the approval of drug by the International Health Authorities. In both studies, sorafenib administered at the dose of 400 mg twice daily demonstrated a statistically significant improvement of overall survival and time to progression than compared to the placebo in patients with well-preserved liver function (Child-Pugh A). Sorafenib proved to be well-tolerated, with skin toxicity (hand-foot skin reaction), diarrhea, and asthenia representing the most common adverse effects. Temporary treatment interruptions and/or dose reductions along with immediate specific treatment of adverse events proved effective in managing adverse drug effects.

In the SHARP trial, the median age of patients treated with sorafenib was 64.9 ± 11.2 years, whereas the Asia-Pacific trial was 51 years (range 23-86). In both studies, the inclusion criteria did not set an upper age limit. The Asia-Pacific study included younger patients on account of the earlier onset of HCC in those regions. The preplanned subgroup analysis according to the patients’ age grouping in the Asia-Pacific study showed that sorafenib provided similar clinical benefits in both younger (< 65 years) and older (≥ 65 years) patients. Following the two registrative trials, the use of sorafenib has also been evaluated in large patient populations treated according to everyday clinical practice.

Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeneNib, is an international, post-approval, prospective, non-interventional study undertaken to evaluate the safety and the efficacy of sorafenib in patients with unresectable HCC, in which the inclusion criteria of patients closely corresponded to that of real-life practices. This study carried out in 39 countries worldwide, enrolled 3,371 patients; of these, 3,202 were available for the evaluation of safety. Two interim analyses (after the accrual of 500 and 1,500 patients, respectively) and the final analysis confirmed the safety profile of sorafenib previously recorded in the phase III pivotal trials, without detecting any new unexpected adverse events. A breakdown of the safety of sorafenib according to age groups was available only for the second interim analysis (1,571 patients). The comparison of sorafenib safety profiles in younger (< 65 years, n = 883) and older patients (≥ 65 years, n = 688) showed that the incidence of adverse events, drug-related adverse events, and serious adverse events was independent of age, similar in both older and younger patients. It is interesting to
note that even the adverse events resulting in permanent discontinuation of the drug were similar in both groups.\[13\]

The impact of age on the effects of sorafenib in clinical practice was also examined in different single and multicenter experiences\[14-20\] and discussed in a few reviews.\[21,22\] A table summarizing the efficacy and the safety of older and younger patients treated with sorafenib reported in most papers so far published are reported [Table 1].

The first non-Asian study investigating the use of sorafenib in a large cohort of elderly patients was published in 2013. Di Costanzo et al.\[14\] analyzed a cohort of consecutive patients not eligible for surgery or loco-regional treatment, with Child-Pugh score $\leq 7$, treated with sorafenib. Clinical outcomes and treatment-related adverse events were compared between younger (< 70 years) and older (≥ 70 years) patients. Overall, 150 patients (90 in the younger and 60 in the older group) were evaluated. The study

### Table 1: Synoptic table outlining the results in younger and older patients with HCC treated with sorafenib

<table>
<thead>
<tr>
<th>Authors</th>
<th>Study design</th>
<th>Efficacy</th>
<th>Safety</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cheng et al.[12]</td>
<td>Open, randomized, preplanned subgroup exploratory analysis</td>
<td>Similar efficacy between &lt; 65 years and &gt; 65 years (OS = 6.5 months)</td>
<td>-</td>
</tr>
<tr>
<td>Lencioni et al.[13]</td>
<td>Open</td>
<td>-</td>
<td>Safety of sorafenib according to age groups only for the second interim analysis (1,571 patients). Comparison of sorafenib safety profile between younger (&lt; 65 years, n = 883) and older patients (≥ 65 years, n = 688) showed that the incidence of adverse events, drug-related adverse events, and serious adverse events was similar in both older and younger patients independently of age</td>
</tr>
<tr>
<td>Di Costanzo et al.[14]</td>
<td>Open</td>
<td>150 patients &lt; 70 years (n = 90); treatment duration = 4 months, TTP = 8 months, OS = 12 months ≥ 70 years (n = 60); treatment duration = 4 months, TTP = 12 months, OS = 16 months</td>
<td>Grades 3-4 AEs: &lt; 70 years (15.7%), ≥ 70 years (9.2%)</td>
</tr>
<tr>
<td>Edeline et al.[15]</td>
<td>Retrospective</td>
<td>129 patients &lt; 70 years (n = 78): PFS = 5.6 months, OS = 9.6 months ≥ 70 years (n = 51): PFS = 5.6 months, OS = 12.6 months</td>
<td>Similar between the two groups: occurrence of severe toxicities (41.0% vs. 51.0%) and hospitalization due to toxicity (9.0% vs. 13.7%). Asthenia and bleeding more frequent in the elderly</td>
</tr>
<tr>
<td>Jo et al.[16]</td>
<td>Retrospective</td>
<td>185 patients &lt; 80 years (n = 161): OS = 10.5 months ≥ 80 years (n = 24): OS = 11.7 months</td>
<td>No difference as for frequency and severity of AEs</td>
</tr>
<tr>
<td>Montella et al.[17]</td>
<td>Retrospective</td>
<td>60 patients &gt; 60 years Disease control rate = 80%, stable disease = 76.6%, TTP = 7 months, OS = 10 months</td>
<td>Thrombosis correlated to TTP. Full doses in 11 out of 60 patients (18.3%)</td>
</tr>
<tr>
<td>Francini and Bianco[18]</td>
<td>Retrospective</td>
<td>31 patients, aged between 70 and 83 years</td>
<td>AEs were reported in all patients, mostly during the 1st month and of grade 1 or 2. Grade 3 side effects: fatigue (22.6%), hand-foot skin reaction (19.3%), thrombocytopenia (12.9%), hyperbilirubinemia (9.7%), abdominal pain (9.7%), and only in one case, diarrhea (3.2%). No grade 4 toxicity Sorafenib has a positive impact on self-sufficiency and quality of life</td>
</tr>
<tr>
<td>Morimoto et al.[19]</td>
<td>Retrospective</td>
<td>76 patients &lt; 75 years (n = 52), ≥ 75 years (n = 24) Average OS and the median TTP were comparable between two dose regimens 400 bid and 400 qb (5.3 months vs. 5.0 months, $P = 0.839$)</td>
<td>The median treatment duration and overall incidence of ADRs were not statistically different with increasing age Subgroup analysis revealed that treatment discontinuation because of ADRs was more frequent among the ≥ 75 years (41.7%) than among the &lt; 75 years (15.0%) AEs with a standard dosage of sorafenib: 41.7% in patients ≥ 75 years and 15.0% in patients &lt; 75 years. This difference is statistically significant. With half-dose regimen, no difference between the age groups was observed</td>
</tr>
<tr>
<td>Wong et al.[20]</td>
<td>Retrospective</td>
<td>172 patients ≥ 70 years (n = 35): PFS = 2.99 months, OS = 5.32 months &lt; 70 years (n = 137): PFS = 3.09 months, OS = 5.16 months</td>
<td>Grades 3-4 AEs: ≥ 70 years (68.6%), &lt; 70 years (62.7%)</td>
</tr>
</tbody>
</table>

HCC: hepatocellular carcinoma; AEs: adverse events; OS: overall survival; TTP: time to progression; PFS: progress free survival; ADRs: adverse drug reactions
showed that in elderly HCC patients with cirrhosis, sorafenib is as safe and effective as in younger patients. No unexpected adverse events related to advanced age were observed. Temporary and permanent sorafenib discontinuations were more frequent in older than in younger patients. However, this difference did not turn out to be statistically significant.

A recently published retrospective study on 129 patients compared the efficacy and safety of sorafenib in HCC patients with different ages (≥ 70 and < 70 years). The efficacy and the overall safety were found to be similar between the two groups. Asthenia and bleeding were more frequent in older patients as a result of a higher use of platelet aggregation inhibitors in this population.

The efficacy and safety of sorafenib in patients ≥ 80 years old were examined in a multicenter Japanese retrospective study. One hundred and eighty-five patients were reviewed, 24 of them being ≥ 80 years old and 161 being < 80 years old. Median overall survival was greater in older patients (11.7 months) than compared to those < 80 years old (10.5 months), with a good tolerability in both groups.

Many elderly patients are frail. Frailty implies a reduced organ function, the presence of comorbidities and impairment of physical function. Concomitant assumption of different drugs could moreover interfere with sorafenib absorption. However, studies on the use of sorafenib in the elderly suggest overcoming the predisposition to consider older patients associated with poor prognosis and poor tolerance to drugs. In these first experiences, in fact, efficacy and safety of sorafenib do not seem influenced by the age. All elderly patients undergoing sorafenib treatment should be strictly monitored to evaluate physical (blood pressure, vital signs) and laboratory parameters to prevent and promptly manage adverse events. Dose adjustments, in order to alleviate adverse events, may be a successful strategy to avoid permanent discontinuation and maximize the benefit of the drug.

A comprehensive geriatric assessment (CGA) should be performed by geriatricians to evaluate the functional and global health status of these elderly patients because CGA results are closely related to the prognosis of elderly patients in general.

CONCLUSION

Given the challenges of managing the complexity of HCC often associated with underlying liver disease and the complex health conditions of elderly patients, it is extremely important to make any decisions on treatment through a multidisciplinary team that includes experts in liver disease and in clinical oncology to perform a personal non-protocol approach for the oncological care and management of elderly patients with HCC. However, elderly patients with good clinical conditions should be treated with sorafenib.

REFERENCES


Source of Support: Nil. Conflict of Interest: None declared.